Lenvima Capsule
Product Images NDC 62856-708

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Lenvima (NDC 62856-708). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eisai Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

The Chemical Structure Of Lenvatinib Mesylate Is Lenvima, A Kinase Inhibitor, Is The Mesylate Salt Of Lenvatinib. Its Chemical Name Is 4-[3-chloro-4-(n’-cyclopropylureido)phenoxy]-7-methoxyquinoline-6 Carboxamide Methanesulfonate. The Molecular Formula Is C21h19cln4o4 • Ch4o3s, And The Molecular Weight Of The Mesylate Salt Is 522.96. (Lenvima 01)

Chemical structure of the active ingredient lenvatinib, showing its molecular framework including aromatic rings, nitrogen, oxygen, chlorine atoms, and a sulfonic acid group. This structure corresponds to lenvatinib mesylate used in the drug Lenvima.*

FDA Label Image

Figure 1: Kaplan-meier Curves For Progression-free Survival In (Lenvima 02)

A survival curve chart comparing progression-free survival over time (months) between Lenvatinib and placebo groups. The y-axis represents progression-free survival probability, and the x-axis represents time in months up to 24. The chart includes the number of subjects at risk for each group at various time points.*

FDA Label Image

Figure 2: Kaplan-meier Curves For Progression-free Survival In Study 205 (Lenvima 03)

A Kaplan-Meier survival probability curve comparing Lenvatinib plus Pembrolizumab (red solid line) and Sunitinib (black dashed line) treatments over time in months, showing survival probabilities on the vertical axis. The number of subjects at risk is indicated below the time axis for both treatment groups.*

FDA Label Image

Figure 3: Kaplan-meier Curves For Overall Survival In Study 205 (Lenvima 04)

A survival probability Kaplan-Meier curve comparing two treatments: Lenvatinib plus Pembrolizumab (red line) versus Sunitinib (black line) over time in months. The chart includes a risk table showing the number of subjects remaining at risk at various time points for each treatment group.*

FDA Label Image

Figure 4: Kaplan-meier Curves For Overall Survival In Reflect (Lenvima 05)

A line graph showing progression-free survival over time in months for two treatment groups: LENVIMA 18 mg plus Everolimus 5 mg (solid line) versus Everolimus 10 mg alone (dashed line). The vertical axis measures progression-free survival proportion, while the horizontal axis shows time from 0 to 24 months. Numbers of subjects at risk at selected time points are displayed below the graph.*

FDA Label Image

Principal Display Panelndc 62856-704-30lenvima(lenvatinib) Capsules4 mg Daily Dose (Lenvima 06)

A survival probability Kaplan-Meier plot comparing LENVIMA (18 mg) plus Everolimus (5 mg) versus Everolimus (10 mg) alone over time in months. The graph shows survival probability on the y-axis and time in months on the x-axis, with the number of subjects at risk listed below the graph for each treatment group at various time points.*

FDA Label Image

Principal Display Panelndc 62856-708-05lenvima(lenvatinib) Capsules8 mg Daily Dose (Lenvima 07)

A Kaplan-Meier survival curve comparing the probability of survival over time in months between Lenvima (Lenvatinib) and Sorafenib treatment groups. The chart shows the number of subjects at risk for each treatment at various time points up to 42 months.*

FDA Label Image

Principal Display Panelndc 62856-710-30lenvima(lenvatinib) Capsules10 mg Daily Dose30 Day Supply10 mg Daily- Dose Carton Containing 6 Cards (Lenvima 08)

A survival probability line graph comparing Lenvima plus Pembrolizumab (blue line) with Doxorubicin or Paclitaxel (orange dashed line) over a time period of 0 to 27 months. The graph includes a survival probability axis from 0 to 1 and a timeline axis in months. A table below the graph shows the number of subjects at risk at various time points for each treatment group.*

FDA Label Image

Principal Display Panelndc 62856-712-30lenvima(lenvatinib) Capsules12 mg Daily Dose (Lenvima 09)

A Kaplan-Meier survival curve graph showing progression-free survival over time in months. The plot compares two treatment groups: Lenvima (Lenvatinib) combined with Pembrolizumab (blue solid line) versus Doxorubicin or Paclitaxel (orange dashed line). The x-axis represents time in months, and the y-axis represents progression-free survival probability. Below the graph is a table indicating the number of subjects at risk in each group at various time points.*

FDA Label Image

Principal Display Panelndc 62856-714-30lenvima(lenvatinib) Capsules14 mg Daily Dose30 Day Supply14 mg Daily- Dose Carton Containing 6 Cards (Lenvima 0a)

Lenvima 4 mg capsules packaging label for oral use by Eisai Inc. The label states a 4 mg daily dose with instructions to take one 4 mg capsule once daily. It includes a 30-day supply, consisting of six cards with five capsules per card. The label features usage instructions with illustrations for opening and dispensing capsules.*

FDA Label Image

Principal Display Panelndc 62856-718-30lenvima(lenvatinib) Capsules18 mg Daily Dose (Lenvima 0b)

Lenvima 8 mg daily dose capsules packaging label showing the brand name and generic name lenvatinib. The label specifies oral capsules with a 30-day supply, instructing to take two 4 mg capsules once daily. The product is labeled Rx only and manufactured by Eisai Inc. The carton includes handling instructions and a barcode.*

FDA Label Image

Principal Display Panelndc 62856-720-30lenvima(lenvatinib) Capsules20 mg Daily Dose30 Day Supply20 mg Daily- Dose Carton Containing 6 Cards (Lenvima 0c)

Lenvima 10 mg daily dose capsules packaging label by Eisai Inc. The label indicates oral capsules of lenvatinib with a 30-day supply. It includes directions on dosage and administration, a barcode, and a detailed push-peel-dispense instruction for capsule management on a carton that contains six cards, each with five 10 mg capsules.*

FDA Label Image

Principal Display Panelndc 62856-724-30lenvima(lenvatinib) Capsules24 mg Daily Dose30 Day Supply24 mg Daily- Dose Carton Containing 6 Cards (Lenvima 0d)

Lenvima 12 mg daily dose capsules carton label for oral use. The label shows Lenvatinib as the active ingredient in capsule form, with instructions to take three 4 mg capsules once daily for a 30-day supply. The labeler is Eisai Inc. The carton contains 12 mg daily-dose packaging with six cards, each containing fifteen 4 mg capsules.*

FDA Label Image

Ndc 62856-704-05lenvima(lenvatinib) Capsules4 mg Daily Dose (Lenvima 0e)

Lenvima 14 mg daily dose capsules packaging label for oral use. The label indicates the product contains lenvatinib capsules with instructions to take one 10 mg capsule and one 4 mg capsule together once daily. It includes a 30-day supply with six cards, each containing five 10 mg and five 4 mg capsules. The labeler is Eisai Inc.*

FDA Label Image

Ndc 62856-708-05lenvima(lenvatinib) Capsules8 mg Daily Dose (Lenvima 0f)

Lenvima (lenvatinib) capsules packaging label for the 18 mg daily dose, oral capsule form. The label shows instructions to take one 10 mg capsule plus two 4 mg capsules together once daily for a 30-day supply. The carton contains six cards, each holding five 10 mg capsules and ten 4 mg capsules. The labeler is Eisai Inc.*

FDA Label Image

Ndc 62856-710-05lenvima(lenvatinib) Capsules10 mg Daily Dose (Lenvima 10)

Packaging label for Lenvima (lenvatinib) capsules, 20 mg daily dose, oral capsule by Eisai Inc. The label includes dosage instructions to take two 10 mg capsules once daily and indicates a 30-day supply. The label shows the product name, strength, dosage form, Rx only status, and barcode with storage and usage directions.*

FDA Label Image

Ndc 62856-712-05lenvima(lenvatinib) Capsules12 mg Daily Dose (Lenvima 11)

Packaging label for Lenvima (lenvatinib) capsules, 24 mg daily dose, by Eisai Inc. The label instructs taking two 10 mg capsules and one 4 mg capsule once daily, with a 30-day supply (six cards total). The label includes usage instructions and handling details for the oral capsules.*

FDA Label Image

Ndc 62856-714-05lenvima(lenvatinib) Capsules14 mg Daily Dose (Lenvima 12)

Lenvima 4 mg capsules packaging label showing a blister card and outer carton. The label includes the proprietary name Lenvima, the generic name lenvatinib, strength of 4 mg, oral capsules dosage form, and Rx only status. Directions indicate taking one 4 mg capsule daily. The labeler is Eisai Inc. The blister card holds seven capsules labeled for daily use.*

FDA Label Image

Ndc 62856-718-05lenvima(lenvatinib) Capsules18 mg Daily Dose (Lenvima 13)

Lenvima 8 mg daily dose capsules packaging label for lenvatinib oral capsules by Eisai Inc. The label shows dosing instructions for taking two 4 mg capsules once daily, with a calendar blister pack design including individual 4 mg capsules and dose tracking slots for five days.*

FDA Label Image

Ndc 62856-720-05lenvima(lenvatinib) Capsules20 mg Daily Dose (Lenvima 14)

Lenvima 10 mg capsules packaging label for oral administration, featuring daily dose instructions. The label includes a calendar-style blister card allowing tracking of daily doses, with six yellow capsules visible. The label displays Lenvatinib as the active ingredient, provided by Eisai Inc., and includes directions to take one 10 mg capsule once daily, with or without food.*

FDA Label Image

Ndc 62856-724-05lenvima(lenvatinib) Capsules24 mg Daily Dose (Lenvima 15)

Lenvima 12 mg daily dose capsules packaging label for oral use by Eisai Inc. The label shows lenvatinib capsules in 4 mg strength, to be taken as three 4 mg capsules daily. Instructions for dosing, including steps to push, peel, and dispense capsules, are illustrated. The carton includes dosage guidance and storage instructions.*

FDA Label Image

Lenvima 16

Lenvima 14 mg daily dose capsules packaging label showing instructions for oral capsules containing lenvatinib. The label details the combination of 10 mg and 4 mg capsules to achieve the 14 mg total daily dose. The labeler is Eisai Inc. It also includes dosing instructions with steps to push, peel, and dispense capsules from blister packaging.*

FDA Label Image

Lenvima 17

Lenvima (lenvatinib) capsules 18 mg daily dose packaging label from Eisai Inc. It includes instructions for taking one 10 mg capsule and two 4 mg capsules together once daily. The label shows dosing instructions, blister pack design, dose strengths of 10 mg and 4 mg capsules, and storage conditions. The product is for oral use and prescription only.*

FDA Label Image

Lenvima 18

Lenvima 20 mg daily dose capsules package label featuring Lenvatinib capsules by Eisai Inc. The label displays 10 mg strength capsules to be taken as two capsules daily for a total of 20 mg. Packaging includes detailed dosing instructions and a blister card with capsules. The design includes the proprietary name Lenvima, generic name Lenvatinib, and dosage form as capsules for oral use.*

FDA Label Image

Lenvima 19

Lenvima (lenvatinib) capsules carton for oral use with 24 mg daily dose. The label includes instructions for taking two 10 mg capsules and one 4 mg capsule daily. The packaging shows individual blister packs labeled with 10 mg and 4 mg capsules, and guidance on dosing with illustrations. Labeler is Eisai Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.